Search research articles
Contact Us
Filters
Showing results (291-300 of 487) with videos related to
Page
of 49
Sort By:
Journal of Immunotherapy and Precision Oncology
|
June 6, 2022
Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma
Timothy P DiPeri, Mehmet Demirhan, Daniel D Karp, et al.
Investigational New Drugs
|
January 8, 2021
The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial
Jeffrey A How, Amir Jazaeri, Shannon N Westin, et al.
Journal of Cutaneous Pathology
|
July 19, 2018
Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor
Krishna Arudra, Ravi Patel, Michael T Tetzlaff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 15, 2017
Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors
Vivek Subbiah, Juneko E Grilley-Olson, Austin J Combest, et al.
JCO Precision Oncology
|
April 23, 2025
Larotrectinib Compared With Real-World Non-Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer
Marcia S Brose, C Benedikt Westphalen, Xiaoyun Pan, et al.
Experimental Hematology & Oncology
|
April 28, 2020
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
Vivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, et al.
Molecular Cancer Therapeutics
|
March 5, 2020
Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies
Roman Groisberg, Jason Roszik, Anthony P Conley, et al.
JCO Precision Oncology
|
September 3, 2021
Retrospective Case Series Analysis of <i>RAF</i> Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies
Andrew Hendifar, Edik M Blais, Brian Wolpin, et al.
Oncotarget
|
August 4, 2016
Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials
J Andrew Livingston, Kenneth R Hess, Aung Naing, et al.
JCO Precision Oncology
|
February 1, 2022
Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study
Julio Peguero, Davendra P S Sohal, Bert H O'Neil, et al.
Page
of 49
Search research articles
Search
Showing results (291-300 of 487) with videos related to
Sort By:
Page
of 49
Journal of Immunotherapy and Precision Oncology
|
June 6, 2022
Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma
Timothy P DiPeri, Mehmet Demirhan, Daniel D Karp, et al.
Investigational New Drugs
|
January 8, 2021
The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial
Jeffrey A How, Amir Jazaeri, Shannon N Westin, et al.
Journal of Cutaneous Pathology
|
July 19, 2018
Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor
Krishna Arudra, Ravi Patel, Michael T Tetzlaff, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 15, 2017
Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors
Vivek Subbiah, Juneko E Grilley-Olson, Austin J Combest, et al.
JCO Precision Oncology
|
April 23, 2025
Larotrectinib Compared With Real-World Non-Tropomyosin Receptor Kinase Inhibitor Therapies in Patients With Tropomyosin Receptor Kinase Fusion Cancer
Marcia S Brose, C Benedikt Westphalen, Xiaoyun Pan, et al.
Experimental Hematology & Oncology
|
April 28, 2020
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial
Vivek Subbiah, Ecaterina Ileana Dumbrava, Yunfang Jiang, et al.
Molecular Cancer Therapeutics
|
March 5, 2020
Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies
Roman Groisberg, Jason Roszik, Anthony P Conley, et al.
JCO Precision Oncology
|
September 3, 2021
Retrospective Case Series Analysis of <i>RAF</i> Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies
Andrew Hendifar, Edik M Blais, Brian Wolpin, et al.
Oncotarget
|
August 4, 2016
Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials
J Andrew Livingston, Kenneth R Hess, Aung Naing, et al.
JCO Precision Oncology
|
February 1, 2022
Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study
Julio Peguero, Davendra P S Sohal, Bert H O'Neil, et al.
Page
of 49